Precision in Practice: Costs and Benefits of Comprehensive Genomic Profiling for Five Stage 4 Cancers
This report evaluates the costs and benefits of comprehensive genomic profiling with next-generation sequencing for five newly diagnosed stage 4 cancers (lung, colorectal, breast, prostate, and pancreatic) vs the current standard of care.
There are potential cost savings, but where do they come from? What other, non-financial benefits could flow from the healthcare system’s use of CGP-NGS? What are the political and logistical challenges that could stand in the way of its general adoption?
Read the full report to get our analysis.
Cette publication est disponible en français.
Key findings
A new lens on cancer care
Evaluating the costs and benefits of CGP-NGS in cancer care
Next steps
Appendix A: Methodology
Appendix B: Bibliography
There are no reviews yet.